Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial
Khorram Khorshid, HR
MetadataShow full item record
ANGIPARS™ is a new herbal extract which has been produced in oral, topical, and intravenous forms. The present article contains preliminary results of the study which was planned to evaluate the efficacy and safety of orally applied ANGIPARS™ and to compare it with the combination of oral and topical forms and also with conventional therapy in patients with diabetic ulcers of the lower extremities. Twenty one patients with diabetic foot ulcers were divided into 3 groups. The first group received 100 mg of oral ANGIPARS™ twice a day for 6 weeks in addition to conventional therapies. In the second group, ANGIPARS™ gel 3% was added to the oral form of the same product besides the conventional therapies for the same period of time. Finally, in the third group which was considered as control, only conventional therapies were performed. The patients were followed for 6 weeks. Parameters such as granulation tissue formation, skin epithelization, and wound surface areas changes were analyzed to determine the effectiveness of the compound in wounds healing. Furthermore, drug safety was assessed by monitoring adverse events and by clinical and laboratory evaluations. The study data showed significant differences between the intervention and control groups with respect to efficacy and tolerability. In each intervention group, primary wound healings occurred following 2 weeks. Complete wound healing which was greater than 70% improvement in wounds surface areas was achieved in 83% and 100% of group 1 and group 2 participants, respectively after 6 weeks. On the other hand, at the same period of time, only 22.2% of patients in control group revealed complete healing. Therefore, ANGIPARS™ had significant positive effect in increasing the incidence of complete wound closure compared with control group (p = 0.042). However, our evaluations indicated that adding topical treatment with 3% gel once a day to the oral therapy with the same product did not make significant difference in healing outcomes statistically (p = 0.769). Clinical and paraclinical evaluations did not show any adverse events during the study. This study showed that in diabetic foot ulcers, either treatment with oral ANGIPARS™ capsules (100mg) twice a day or combination therapy with oral and topical forms, in conjunction with good wound care significantly increased the incidence of complete wound closure. In addition, the application of this product was safe and did not make any unexpected adverse event.
Showing items related by title, author, creator and subject.
Evaluation of platelet-rich plasma gel potential in acceleration of wound healing duration in patients underwent pilonidal sinus surgery: A randomized controlled parallel clinical trial Mohammadi, S; Nasiri, S; Mohammadi, MH; Malek Mohammadi, A; Nikbakht, M; Zahed Panah, M; Safar, H; Mostafaei, S; Norooznezhad, AH; Soroosh, AR; Alimoghaddam, K; Ghavamzadeh, A (2017)Objectives One of the most important surgical issues applied in the treatment of pilonidal sinus disease is wound healing. The aim of this study was to investigate the possible effect of platelet-rich plasma (PRP) gel on ...
Effects of intravenous Semelil (ANGIPARS™) on diabetic foot ulcers healing: A multicenter clinical trial Larijani, B; Heshmat, R; Bahrami, A; Delshad, H; Ranjbar Omrani, G; Mohammad, K; Heidarpour, R; Mohajeri Tehrani, MR; Kamali, K; Farhadi, M; Gharibdoust, F; Madani, SH (2008)Some diabetic foot ulcers, which are notoriously difficult to cure, are one of the most common health problems in diabetic patients .There are several surgical and medical options which already have been introduced for ...
Evaluation of wound healing in diabetic foot ulcer using platelet-rich plasma gel: A single-arm clinical trial Mohammadi, MH; Molavi, B; Mohammadi, S; Nikbakht, M; Mohammadi, AM; Mostafaei, S; Norooznezhad, AH; Ghorbani Abdegah, A; Ghavamzadeh, A (2017)The aim of the present study was to evaluate the effectiveness of using autologous platelet-rich plasma (PRP) gel for treatment of diabetic foot ulcer (DFU) during the first 4 weeks of the treatment. In this longitudinal ...